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Ralph Steinman is to receive the 2007 Albert Lasker Award for Basic Medical Research 
for his discovery of dendritic cells and his path-breaking work demonstrating their central 
role as the principal antigen-presenting cells of the immune system and key activators of 
T cell responses.This year’s Albert Lasker Award for 
Basic Medical Research is to be con-
ferred on Ralph M. Steinman, Henry 
G. Kunkel Professor and Senior Physi-
cian at New York’s Rockefeller Univer-
sity, for his discovery of dendritic cells 
(DCs) and for demonstrating that they 
are the principal antigen-presenting 
cells of the immune system. Steinman 
showed that the state of activation and 
differentiation of DCs determines both 
the magnitude and the nature of the 
adaptive immune responses mounted 
by an individual, thus revealing that 
the DC is the central interpreter of the 
nature of the threat posed by a foreign 
entity and the key determinant of the 
type of immune response that should 
be mounted.
Steinman showed that a previ-
ously unrecognized population of 
stellate cells (Figure 1) found in vir-
tually every organ of the body con-
tinuously samples the local envi-
ronment, processing antigens and 
presenting them to other immune 
cells. He further discovered that 
the state of activation and differ-
entiation of these cells determines 
both the magnitude and the nature 
of the adaptive immune responses 
mounted by an individual. Dendritic 
cells both maintain peripheral tol-
erance to self-antigens and initiate 
immunity to foreign substances. 
Indeed, it may be said that DCs are 
the sentinel cells that ensure that an 
immune response is appropriate in 
specificity, intensity, and type to the 
nature of the threat posed by the 
antigen-bearing entity.
The immune response may be 
thought of as guided by three princi-
ples or laws. The first is that immune responses of immense diversity can 
be generated (Universality). The sec-
ond is that powerful mechanisms 
exist to prevent or limit responses to 
self (Tolerance), and the third is that 
responses are mounted only to enti-
ties that constitute a threat and the 
response mounted is appropriate to 
the type of threat (Appropriateness). 
This third critical element of immu-
nity had largely been ignored prior 
to Steinman’s work because immu-
nologists concerned themselves with 
the two other major themes, that is, 
how specificity is generated and how 
autoimmune responses are avoided Cell 130, Septeor controlled. The principle of “appro-
priateness” of a response could be 
grappled with only when the cell 
responsible for the initiation of that 
response could be studied.
Establishing how the immune sys-
tem is organized to enforce each of 
these laws represented great scien-
tific accomplishments. The analysis 
of how immune responses of virtually 
unlimited diversity are created began 
with the recognition that individual 
lymphocytes expressed receptors of 
only a single specificity and that the 
selectable element of the immune 
system was the lymphocyte (clonal Figure 1. Pathways of DC Activation
Shown are the pathways through which dendritic cells (DCs) become activated as a result of 
infection (adapted from Reis e Sousa, 2001). (Inset) The first glimpse of a dendritic cell. Re-
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selection). For the precursors of anti-
body-secreting cells (B cells), it was 
clear that the receptor of the cell and 
the initial antibody product of the cell 
would have identical antigen-com-
bining sites.
The central enigma of how to cre-
ate diversity was solved brilliantly 
when molecular biology could be 
applied to lymphocytes. It was dem-
onstrated that recombination allowed 
single members of distinct families 
of genetic elements to be assembled 
into genes that encoded the variable 
regions of the H and L chains of anti-
bodies. Furthermore, at the positions 
where these elements joined, a “ran-
dom sequence generator” created a 
virtually unlimited set of sequences 
that are found in antibody molecules 
at the sites shown by structural analy-
sis to contact antigen. This strategy 
allowed a relatively limited amount of 
genetic information to create a virtually 
unlimited number of distinct antigen-
combining sequences. Indeed, the 
potential number of distinct antibodies 
(and T cell receptors) far exceeds the 
actual number of lymphocytes in the 
body. Although the principle of diver-
sity generation for T cells is essentially 
the same as for antibodies, the T cell-
recognition mechanism has a critical 
“twist” that brings into play an entirely 
new principle of recognition in the 
immune system and, indeed, under-
lies much of the importance of the 
Steinman discovery.
Antibodies recognize structures 
found on the surface of microbial 
pathogens and other antigenic sub-
stances, consistent with their major 
function of eliminating pathogens 
prior to their entry into a cell. By con-
trast, T cells recognize structures 
derived from entities that are within 
cells, either endogenously synthe-
sized or imported into the cell by 
infection or by various uptake mecha-
nisms. How T cells “see” intracellular 
molecules was the great enigma that 
made understanding T cell antigen 
recognition the “holy grail” of immu-
nology from the 1960s to the 1980s. 
Indeed, there are actually two distinct 
recognition events in the T cell activa-
tion process. The first, and unantici-
pated, one was that the cell in which 968 Cell 130, September 21, 2007 ©2007the antigen resided was able to gener-
ate peptides derived from the antigen 
and to load them into a specialized 
set of proteins, the major histocom-
patibility complex (MHC) molecules. 
MHC molecules with their loaded 
peptides were then shuttled to the cell 
surface, where they were available for 
recognition by T cell receptors of the 
appropriate specificity. The peptide-
loading event depended upon the 
capacity of a binding site within the 
MHC molecule to recognize key ele-
ments in the peptide sequence and 
to bind that peptide depending on 
this recognition. Thus, both the MHC 
molecule and the T cell receptor may 
be thought of as antigen-recognition 
molecules that are key to T cell acti-
vation. Simple expression of peptide/
MHC complexes on the cell surface 
is, however, insufficient for activation 
of a T cell, even one that expresses a 
receptor that could interact with that 
complex with high affinity. For the ini-
tiation of a T cell response, presen-
tation of antigen needs to be medi-
ated by a specialized cell endowed 
with a set of properties that allows an 
appropriate response to ensue.
Of course, that specialized cell is 
Steinman’s dendritic cell (DC). Stein-
man first described the DC in a series 
of papers, published between 1973 
and 1975, when he was a postdoc-
toral fellow in the laboratory of the 
late Zanvil Cohn at the Rockefeller 
University (Steinman and Cohn, 1973, 
1974; Steinman et al., 1974, 1975). 
Steinman and Cohn and their col-
leagues showed that DCs are widely 
distributed in lymphoid organs (later, 
it was recognized that these cells are 
found in virtually every organ). Stein-
man worked out techniques to obtain 
this rare cell type with high purity and 
to maintain these cells in culture. He 
showed that DCs are the major (if not 
sole) stimulants of the mixed lympho-
cyte response (MLR), a laboratory 
surrogate of an immune response. 
DCs are at least 100 to 300 times 
more potent in initiating this response 
than are other cells, mainly B cells 
and macrophages, that also express 
the principle stimulants of MLRs, the 
class II MHC molecules (Steinman 
et al., 1983). Furthermore, DCs were  Elsevier Inc.shown to be extremely efficient stim-
ulants of more conventional antigen-
specific responses by CD4 T cells 
and to be potent inducers of antigen-
specific cytotoxic T cell responses 
(Nussenzweig et al., 1980).
With his colleagues, Steinman dem-
onstrated that DCs exist in the human 
as well as the mouse and that they 
could be found in human blood (Van 
Voorhis et al., 1982). He and his col-
leagues developed important tools to 
study DCs, including key monoclonal 
antibodies that not only made DC iden-
tification more straightforward but also 
proved to be specific for molecules 
with important functional and target-
ing roles. An important insight into DC 
physiology was the recognition that an 
epidermal cell, the Langerhans cell, 
would develop into a DC in tissue cul-
ture but that the two cell types differed 
in several critical features (Schuler and 
Steinman, 1985). The Langerhans cell 
expresses Fc receptors, allowing it to 
efficiently capture exogenous antigens 
in immune complexes, but it lacks 
surface expression of class II MHC 
molecules, making it ineffective as an 
antigen-presenting cell. By contrast, 
the DC derived from the Langerhans 
cell lacks Fc receptors and other anti-
gen-capture molecules but expresses 
extremely high levels of MHC mole-
cules allowing it to be a highly efficient 
antigen-presenting cell.
This insight led to the concept 
that Langerhan’s cells and other 
types of tissue DCs act as sentinels 
throughout the body, efficiently cap-
turing newly introduced antigens or 
antigens initially taken up by, or pro-
duced in, other cell types (Figure 1). 
Indeed, cells of the DC family were 
subsequently shown to express a 
variety of cell-surface molecules in 
addition to Fc receptors that allow 
them to capture antigens. These 
include receptors for complement, 
mannose receptors and lectins, and 
also receptors for dying cells, to 
name but a few. Furthermore, DCs 
possess receptors (including Toll-
like receptors) that enable them to 
detect the presence of potential 
pathogens, as well as receptors that 
serve as a link to other cells of the 
innate immune system.
Under stimulatory conditions such 
as a local infection or inflammatory 
response, tissue DCs migrate to cen-
tral lymphoid tissues, particularly 
the draining lymph nodes, carrying 
with them their ingested antigens. 
Such stimulated DCs also upregulate 
MHC molecules and enhance their 
antigen-processing capacity so that 
they now efficiently display peptide/
MHC complexes on their surface; 
many of these peptides are derived 
from the pathogen or from other 
antigens present in the tissue. Naive 
lymphocytes, including those spe-
cific for the peptide/MHC complexes 
expressed on the immigrating matur-
ing DCs, are found in the T cell zone 
of the spleen and lymph nodes and, 
depending upon other properties of 
the DC, may receive potent stimula-
tion to initiate the massive expansion 
and differentiation that characterize 
immune responses. A population of 
DCs resident in lymphoid tissues also 
exist. Although these express the 
MHC molecules needed for antigen 
presentation, they may be regarded 
as nonactivated and fail to express 
many of the self-surface molecules 
or to produce several of the cytokines 
expressed by tissue-activated DCs.
Let’s now turn back to the role of 
the DC in imposing the Law of Appro-
priateness of the immune response. 
Indeed, interest in this phenom-
enon stems from a 1989 proposal 
by Charles A. Janeway that immune 
responses are regulated in amount 
and kind by interactions between 
pathogens and the innate immune 
system (Janeway, 1989). Janeway pro-
posed his now famous concept that 
pathogens express certain essential 
molecules that they could not easily 
alter; these serve as pathogen-asso-
ciated molecular patterns (PAMPs). 
He postulated that cells of the innate 
immune system possess receptors 
for these entities, pattern recognition 
receptors (PRRs). The recognition of 
PAMPs by innate immune cells led 
to their instruction of the adaptive 
immune system as to whether and 
how it should respond to a microbial 
or other antigenic challenge. Jules 
Hoffman and his colleagues (Lemaitre 
et al., 1996) demonstrated that a mol-ecule called Toll (previously identified 
in a genetic screen of dorsal-ventral 
pattern determination in Drosophila) 
unexpectedly also is required for 
antimicrobial resistance in flies, acti-
vating a signaling pathway analogous 
to the NF-κB pathway in mammalian 
cells. Then, in 1997, Janeway and his 
colleagues (Medzhitov et al., 1997) 
isolated a human homolog of Toll (a 
Toll-like receptor) and showed that it 
too could activate the NF-κB path-
way, thereby inducing the expression 
of critical innate immune mediators. It 
became clear that the DC is the main 
“measurer” of the threat posed by 
a given introduced antigen-bearing 
entity, such as a microbial pathogen, 
because of its ability to recognize and 
respond to pathogens and to receive 
signals from other cell types that are 
responding to pathogens. Nonac-
tivated DCs in tissues and resident 
DCs in lymphoid organs that had not 
been stimulated by ligands of Toll-like 
receptors failed to express a set of 
key “costimulatory molecules” and to 
produce important cytokines that are 
jointly essential for efficient induc-
tion of T cell responses. By contrast, 
appropriately activated DCs express 
the costimulants CD80 and CD86 and 
may produce the cytokines IL-12 and 
IL-23. Recently, activation of DCs was 
found to induce production of Notch 
ligands, which also may have a guid-
ing role for the immune response.
Evidence exists that the type of 
DC and its differentiated state may 
direct responding T cells down differ-
ent fate pathways. Thus, IL-12 and IL-
23, which may be made by dendritic 
cells, will help in the first instance 
to promote Th1 differentiation by 
responding T cells and in the second 
to sustain differentiated Th17 cells. IL-
10 produced by other DCs may favor 
induction of regulatory T cells. It has 
been argued that the expression of 
inducible costimulator (ICOS) ligand 
by DCs plays an important role in Th2 
development as does the expression 
of particular Notch ligands.
Steinman and his colleagues 
showed that nonactivated DCs that 
express large numbers of MHC mol-
ecules could be efficient inducers 
of peripheral T cell tolerance. In an Cell 130, Sepelegant study, Michel Nussenzweig, 
Steinman, and their associates pro-
vided evidence that when antigens 
are targeted to nonactivated DCs, 
the outcome of the interaction of that 
DC with the T cell bearing a cognate 
receptor is tolerance (Hawiger et al., 
2001; Bonifaz et al., 2002). These 
investigators proposed that imma-
ture DCs in secondary lymphoid tis-
sues are continuously processing 
self-antigens, either endogenously 
produced within the DC or acquired 
by endocytosis from tissue fluid or 
from other cell types. These DCs 
then present the processed antigens 
to any T cells that may be specific for 
such self-antigens, rendering them 
tolerant. This immature DC-based 
tolerance may provide an important 
mechanism for maintaining a state of 
peripheral tolerance to self-antigens. 
Such continuous tolerance enforce-
ment should serve to protect an indi-
vidual against making a response to 
self-antigens when DCs are activated 
and are presenting both foreign and 
self-antigens. Those T cells spe-
cific for foreign antigens should be 
capable of responding, but those 
specific for self-antigens should have 
been eliminated or rendered toler-
ant through prior interactions, thus 
protecting the individual from devel-
oping autoimmunity in the course of 
responses to microbial pathogens.
What started as a single paper in 
the Journal of Experimental Medicine 
in 1973 is, according to the Institute 
of Scientific Information, only one of 
more than 35,000 papers published 
on DCs, with more than 20 of these 
having received over 1,000 citations. 
Indeed, it is no longer appropriate to 
think of DCs as a single cell type. It is 
clear that multiple types of DCs exist, 
with given tissues possessing several 
phenotypically and functionally dis-
tinct DC populations, each located 
in a precise position within the lym-
phoid organ.
Efforts are underway to take advan-
tage of the unique properties of DCs 
for vaccine development. One could 
consider mechanisms to uniquely tar-
get antigens to activated DCs or alter-
natively to incorporate antigens into 
DCs in vitro with the goal of injecting tember 21, 2007 ©2007 Elsevier Inc. 969
antigen-loaded activated DCs into an 
organism to elicit a strong immune 
response. This strategy has been 
the focus of work aimed at develop-
ing therapeutic vaccines to shrink 
tumors. Given that many tumors are 
known to exert strong immunosup-
pressive effects, the singular potency 
of dendritic cell-based immunogens 
could have a striking effect.
The choice of Ralph Steinman to 
receive the 2007 Albert Lasker Award 
for Basic Medical Research hon-
ors a unique discovery of immense 
importance both for understanding 
the organization and regulation of the 
immune response and for manipulating 
the immune system to either enhance 
responses or, under the right circum-
stances, achieve tolerance. Steinman’s 
achievement is particularly notewor-
thy in that he began as a lonely voice, 970 Cell 130, September 21, 2007 ©200championing an idea that was not at all 
popular, and through the sheer weight 
of the growing body of evidence that he 
and his colleagues amassed turned the 
study of DCs from a one-lab operation 
to one of the dominant themes of mod-
ern immunology.
ReFeRenCes
Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, 
M., Nusseenzweig, M.C., and Steinmen, R.M. 
(2002). J. Exp. Med. 196, 1627–1638.
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., 
Mahnke, K., Rivera, M., Ravetch, J.V., Stein-
man, R.M., and Nussenzweig, M.C. (2001). J. 
Exp. Med. 194, 769–779.
Janeway, C. A. (1989). Cold Spring Harb. 
Symp. Quant Biol. 54, 1–13. 
Lemaitre, B., Nicolas, E., Michaut, L., Reich-
hart, J.-M., and Hoffmann, J.A. (1996). Cell 
86, 973–983.
Medzhitov, R., Preston-Hurlburt, P., and Jane-7 Elsevier Inc.way, C.A., Jr. (1997). Nature 388, 394–397.
Nussenzweig, M.C., Steinman, R.M., Gutchinov, 
B., and Cohn, Z.A. (1980). J. Exp. Med. 152, 
1070–1084.
Reis e Sousa, C. (2001). Immunity 14, 495–498.
Schuler, G., and Steinman, R.M. (1985). J. Exp. 
Med. 161, 526–546.
Steinman, R.M., and Cohn, Z.A. (1973). J. Exp. 
Med. 137, 1142–1162.
Steinman, R.M., and Cohn, Z.A. (1974). J. Exp. 
Med. 139, 380–397.
Steinman, R.M., Lustig, D.S., and Cohn, Z.A. 
(1974). J. Exp. Med. 139, 1431–1445.
Steinman, R.M., Adams, J.C., and Cohn, Z.A. 
(1975). J. Exp. Med. 141, 804–820.
Steinman, R.M., Gutchinov, B., Witmer, M.D., 
and Nussenzweig, M.C. (1983). J. Exp. Med. 
157, 613–627.
Van Voorhis, W.C., Hair, L.S., Steinman, R.M., 
and Kaplan, G. (1982). J. Exp. Med. 155, 1172–
1187.
